Eye drop developer Oculis showcases positive PhII data; Aquestive hunts for another FDA OK
→ Ophthalmology-focused Swiss drug developer Oculis has rolled out positive data from their Phase II study of OCS-01 — an eye …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
